|
Fördröjd
Andra börsplatser
|
5-dagars förändring | Förändring 1 jan. | ||
| 1,260 USD | −59,35 % |
|
-.--% | - |
| 12-16 | Sonnet BioTherapeutics Holdings, Inc. rapporterar resultat för helåret som slutade den 30 september 2025 | CI |
| 12-02 | Största Nedgångarna Mitt på Dagen | MT |
| Skatteperiod: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Revenues | 484 tn | 350 tn | 148 tn | 18,63 tn | 1 mn | |||
Total Revenues | 484 tn | 350 tn | 148 tn | 18,63 tn | 1 mn | |||
Cost of Goods Sold, Total | 16,63 mn | 21,44 mn | 11,81 mn | 5,74 mn | 8,36 mn | |||
Gross Profit | −16,15 mn | −21,09 mn | −11,67 mn | −5,72 mn | −7,36 mn | |||
Selling General & Admin Expenses, Total | 8,94 mn | 8,58 mn | 7,13 mn | 6,13 mn | 8,49 mn | |||
R&D Expenses | - | - | - | - | - | |||
Other Operating Expenses, Total | 8,94 mn | 8,58 mn | 7,13 mn | 6,13 mn | 8,49 mn | |||
Operating Income | −25,09 mn | −29,67 mn | −18,79 mn | −11,85 mn | −15,84 mn | |||
Interest Expense, Total | - | - | - | - | −556 tn | |||
Interest And Investment Income | 15 | - | - | - | - | |||
Net Interest Expenses | 15 | - | - | - | −556 tn | |||
Currency Exchange Gains (Loss) | −22,04 tn | −52,48 tn | −40,08 tn | 84,29 tn | −113 tn | |||
Other Non Operating Income (Expenses) | - | - | - | 4,33 mn | 720 tn | |||
EBT, Excl. Unusual Items | −25,11 mn | −29,72 mn | −18,83 mn | −7,44 mn | −15,79 mn | |||
In Process R&D Expenses | - | - | - | - | - | |||
Other Unusual Items | 126 tn | - | - | - | - | |||
EBT, Incl. Unusual Items | −24,98 mn | −29,72 mn | −18,83 mn | −7,44 mn | −15,79 mn | |||
Income Tax Expense | - | - | - | - | 218 tn | |||
Earnings From Continuing Operations | −24,98 mn | −29,72 mn | −18,83 mn | −7,44 mn | −16,01 mn | |||
Net Income to Company | −24,98 mn | −29,72 mn | −18,83 mn | −7,44 mn | −16,01 mn | |||
Net Income - (IS) | −24,98 mn | −29,72 mn | −18,83 mn | −7,44 mn | −16,01 mn | |||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||
Net Income to Common Incl Extra Items | −24,98 mn | −29,72 mn | −18,83 mn | −7,44 mn | −16,01 mn | |||
Net Income to Common Excl. Extra Items | −24,98 mn | −29,72 mn | −18,83 mn | −7,44 mn | −16,01 mn | |||
Per aktie poster | ||||||||
Net EPS - Basic | - | −1,2 tn | −145,12 | −11,35 | −3,92 | |||
Basic EPS - Continuing Operations | - | −1,2 tn | −145,12 | −11,35 | −3,92 | |||
Basic Weighted Average Shares Outstanding | - | 24,7 tn | 130 tn | 655 tn | 4,08 mn | |||
Net EPS - Diluted | - | −1,2 tn | −145,12 | −11,35 | −3,92 | |||
Diluted EPS - Continuing Operations | - | −1,2 tn | −145,12 | −11,35 | −3,92 | |||
Diluted Weighted Average Shares Outstanding | - | 24,7 tn | 130 tn | 655 tn | 4,08 mn | |||
Normalized Basic EPS | - | −751,92 | −90,7 | −7,09 | −2,42 | |||
Normalized Diluted EPS | - | −751,92 | −90,7 | −7,09 | −2,42 | |||
Kompletterande punkter | ||||||||
EBITDA | −25,07 mn | −29,66 mn | −18,78 mn | −11,84 mn | −15,83 mn | |||
EBITA | −25,09 mn | −29,67 mn | −18,79 mn | −11,85 mn | −15,84 mn | |||
EBIT | −25,09 mn | −29,67 mn | −18,79 mn | −11,85 mn | −15,84 mn | |||
EBITDAR | −24,96 mn | −29,56 mn | −18,68 mn | −11,74 mn | −15,74 mn | |||
Effective Tax Rate - (Ratio) | - | - | - | - | −1,38 | |||
Normalized Net Income | −15,69 mn | −18,58 mn | −11,77 mn | −4,65 mn | −9,87 mn | |||
Interest on Long-Term Debt | - | - | - | - | - | |||
Kompletterande driftskostnadsposter | ||||||||
General and Administrative Expenses | 8,94 mn | 8,58 mn | 7,13 mn | 6,13 mn | 8,49 mn | |||
Research And Development Expense From Footnotes | 16,63 mn | 21,44 mn | 11,81 mn | 5,74 mn | 8,36 mn | |||
Net Rental Expense, Total | 115 tn | 100 tn | 96,82 tn | 92,31 tn | 94,12 tn | |||
Imputed Operating Lease Interest Expense | - | - | - | - | 4,72 mn | |||
Imputed Operating Lease Depreciation | - | - | - | - | −4,63 mn | |||
Stock-Based Comp., COGS (Total) | 423 tn | 438 tn | 121 tn | 109 tn | 66,9 tn | |||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | - | |||
Stock-Based Comp., G&A Exp. (Total) | 953 tn | 438 tn | 127 tn | 122 tn | 133 tn | |||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||
Total Stock-Based Compensation | 1,38 mn | 876 tn | 249 tn | 231 tn | 200 tn |
- Börsen
- Aktier
- SONN Aktie
- Finanser Sonnet Biotherapeutics
- Resultaträkning
Välj din utgåva
All finansiell information anpassad till den nationella nivån
















